Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult‐onset Still’s disease receiving interleukin‐6 inhibitor treatment-Reference-Cited by-同舟云学术

Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult‐onset Still’s disease receiving interleukin‐6 inhibitor treatment

Published:2022-06-19 Issue:9 Volume:25 Page:1003-1012
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J of Rheum Dis

Author:

Naniwa Taio¹²^ORCID,Yamabe Toru¹²^ORCID,Ohmura Shin‐ichiro³^ORCID,Uehara Koji¹²^ORCID,Tamechika Shin‐ya¹²^ORCID,Maeda Shinji¹²^ORCID,Isogai Shuntaro¹²,Wada Junichi²⁴^ORCID

Affiliation:

1. Division of Rheumatology Department of Internal Medicine Nagoya City University Hospital Nagoya Japan

2. Department of Respiratory Medicine, Allergy and Clinical Immunology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

3. Department of Rheumatology Seirei Hamamatsu General Hospital Hamamatsu Japan

4. Department of Rheumatology Toyokawa City Hospital Toyokawa Japan

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.14371

Reference48 articles.

1. Still's disease in the adult.

2. Mechanisms, biomarkers and targets for adult-onset Still’s disease

3. Macrophage activation syndrome: advances towards understanding pathogenesis

4. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature

5. Elevated serum interleukin 6, interferon‐gamma, and tumor necrosis factor‐alpha levels in patients with adult Still’s disease;Hoshino T;J Rheumatol,1998

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Free interleukin-18 is elevated in CD22 CAR T-cell–associated hemophagocytic lymphohistiocytosis–like toxicities;Blood Advances;2023-10-12

2. Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience;Rheumatology and Therapy;2023-10-04

3. Tocilizumab;Reactions Weekly;2023-07-01